Media
Artax Biopharma is on a mission to develop new drug candidates which reset the body’s autoimmune system to give normal, healthy responses again in patients with T cell mediated autoimmune diseases.
1 in 10 individuals is affected by autoimmune disease – our mission is to treat them
Autoimmune diseases affect many of us, and we currently lack treatments which restore a more normal autoimmune response without causing immune suppression. Artax Biopharma aims to fill this gap with its pipeline of Nck modulators.
Recent news and publications
-
- Scientific Publications
First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T cell Receptor Signal Modulator AX-158
D. Scott Batty presented the first-in-human Phase 1 trial results of AX-158 at ACR Convergence… -
- Scientific Publications
TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases
Christopher VanDeusen presented data on the mechanism of action of AX-158, a first-in-class Nck modulator, at… -
- Press Releases
Artax Biopharma to present first-in-class Nck modulator mechanism of action and Phase 1 data at the ACR Annual Meeting
Cambridge, MA, October 1, 2024 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on…